【赛诺菲与箕星就Aficamten在大中华区市场达成协议】金十数据12月20日讯，12月20日，赛诺菲(SNY.O)与箕星药业共同宣布签订正式协议，协议约定赛诺菲将收购箕星在大中华区独家开发和商业化Aficamten的权益。该交易预计于2024年内完成，交易金额不对外公开。中国国家药品监督管理局（NMPA）药品审评中心（CDE）和美国食品药品监督管理局（FDA）均已受理Aficamten用于治疗梗阻性肥厚型心肌病的新药上市申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.